| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Regulation and Neuroendocrinology Section (S.A., N.J.S., J.K., X.F., P.M.Y.), Clinical Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, and Surgical Neurology Branch (E.H.O.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892; Departments of Pediatrics and Medicine (S.R.), University of Chicago, Chicago, Illinois 60637; and Cold Spring Harbor Laboratory (M.Q.Z.), Cold Spring Harbor, New York 11724
Patients with TSH-secreting pituitary tumors (TSHomas) have high
serum TSH levels despite elevated thyroid hormone levels. The mechanism
for this defect in the negative regulation of TSH secretion is not
known. We performed RT-PCR to detect mutations in TRß from a
surgically resected TSHoma. Analyses of the RT-PCR products revealed a
135-bp deletion within the sixth exon that encodes the ligand-binding
domain of TRß2. This deletion was caused by alternative splicing of
TRß2 mRNA, as near-consensus splice sequences were found at the
junction site and no deletion or mutations were detected in the tumoral
genomic DNA. This TRß variant (TRß2spl) lacked thyroid hormone
binding and had impaired T3-dependent negative regulation
of both TSHß and glycoprotein hormone
-subunit genes in
cotransfection studies. Furthermore, TRß2spl showed dominant negative
activity against the wild-type TRß2. These findings strongly suggest
that aberrant alternative splicing of TRß2 mRNA generated an abnormal
TR protein that accounted for the defective negative regulation of TSH
in the TSHoma. This is the first example of aberrant alternative
splicing of a nuclear hormone receptor causing hormonal dysregulation.
This novel posttranscriptional mechanism for generating abnormal
receptors may occur in other hormone-resistant states or tumors in
which no receptor mutation is detected in genomic DNA.
This article has been cited by other articles:
![]() |
S. H. Long, M. J. Berna, M. Thill, A. Pace, T. K. Pradhan, K. M. Hoffmann, J. Serrano, and R. T. Jensen Secretin-Receptor and Secretin-Receptor-Variant Expression in Gastrinomas: Correlation with Clinical and Tumoral Features and Secretin and Calcium Provocative Test Results J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4394 - 4402. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mamanasiri, S. Yesil, A. M. Dumitrescu, X.-H. Liao, T. Demir, R. E. Weiss, and S. Refetoff Mosaicism of a Thyroid Hormone Receptor-{beta} Gene Mutation in Resistance to Thyroid Hormone J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3471 - 3477. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Furumoto, H. Ying, G. V. R. Chandramouli, L. Zhao, R. L. Walker, P. S. Meltzer, M. C. Willingham, and S.-Y. Cheng An Unliganded Thyroid Hormone {beta} Receptor Activates the Cyclin D1/Cyclin-Dependent Kinase/Retinoblastoma/E2F Pathway and Induces Pituitary Tumorigenesis Mol. Cell. Biol., January 1, 2005; 25(1): 124 - 135. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kato, H. Ying, M. C. Willingham, and S.-Y. Cheng A Tumor Suppressor Role for Thyroid Hormone {beta} Receptor in a Mouse Model of Thyroid Carcinogenesis Endocrinology, October 1, 2004; 145(10): 4430 - 4438. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lania, G. Mantovani, and A. Spada Genetics of Pituitary Tumors: Focus on G-Protein Mutations Experimental Biology and Medicine, October 1, 2003; 228(9): 1004 - 1017. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Liu and R. B. Altman Large scale study of protein domain distribution in the context of alternative splicing Nucleic Acids Res., August 15, 2003; 31(16): 4828 - 4835. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Spada and P. Beck-Peccoz Editorial: New Strategy to Solve the Etiopathogenetic Conundrum of Pituitary Adenomas Endocrinology, February 1, 2002; 143(2): 343 - 346. [Full Text] [PDF] |
||||
![]() |
S. Ando, N. J. Sarlis, E. H. Oldfield, and P. M. Yen Somatic Mutation of TR{beta} Can Cause a Defect in Negative Regulation of TSH in a TSH-Secreting Pituitary Tumor J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5572 - 5576. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |